Caricamento...
Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m(−2) was given on days 1, 8 and 15 every 4 weeks, while vindesine 3 mg m(−...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group
1999
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2362682/ https://ncbi.nlm.nih.gov/pubmed/10070884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690140 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|